Neuropharmacology Market Analysis and Reports | Germany Conference Series

Market Analysis - Neuropharmacology 2018

Summary: Neuropharmacology 2018 welcomes attendees, presenters, and exhibitors from all over the world to Frankfurt, Germany. We are delighted to invite you all to attend and register for the “9th Global Experts Meeting on Neuropharmacology (Neuropharmacology 2018)” which is going to be held during November 15-16, 2018 Frankfurt, Germany. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Neuropharmacology-2017, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Neuropharmacology 2018 organizing committee look forward to meet you at Frankfurt, Germany.

For more details please visit   http://neuro.pharmaceuticalconferences.com/

Importance and Scope:  Neuropharmacology is the study of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behaviour. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more.

Comparative analysis for Neurological Disorders (Age wise profile)

Conference Highlights

  • Neuroimmunology and Neuroinflammation
  • Neural Stem Cell
  • Molecular Neuropharmacology
  • Clinical Neuropharmacology
  • Psychopharmacology
  • Neurochemical Transmission
  • Behavioral and Addiction Neuropharmacology
  • Neurotechnology
  • Neuroendocrinology
  • Alzheimer’s Disease and Dementia
  • Parkinson’s Disease
  • Neuroethics
  • Future Aspects of Neuropharmacology
  • Case Study Reports

Attendance Profile according to specialization in a Neuroscience Conference

Hospitals of Neuropharmacology

Top Hospitals

  • Mayo Clinic, Rochester, Minnesota
  • Johns Hopkins Hospital, Baltimore, Maryland
  • Massachusetts General Hospital, Boston
  • University of California–San Francisco Medical Center
  • Mathodist Hospital, San Antonio
  • University of California–Los Angeles Medical Center
  • New York University Langone Medical Center, New York City
  • Hospitals of the University of Pennsylvania–Penn Presbyterian
  • Northwestern Memorial Hospital, Chicago
  • Baptist Medical Centre, San Antonio

 Major Neuropharmacology related Associations around the Globe

  • Canadian Neurological Sciences Federation
  • European Parkinson’s disease Association
  • Malaysian Society of Neurosciences
  • Eurospine, The Spine Society Of Europe
  • The Spanish Society of Neurology (SEN)
  • The Czech Neuropsychopharmacological Society
  • Belgian Neurological Society
  • National Neurotrauma Society
  • National Parkinson'S Foundation
  • European Society Of Neurosonology And Cerebral Hemodynamics
  • Federation Of European Neuroscience Societies
  • Malaysian Society Of Neurosciences
  • Česká Neurologická Společnost
  • The Czech Neuropsychopharmacological Society
  • European Academy Of Neurology
  • Deutsche Gesellschaft Fur Neurologieologie
  • International Brain Research Organization
  • The Neuropathy Association
  • The Primary Care Neurology Society
  • The Spanish Society Of Neurology (SEN)

Major Neuropharmacology related Associations

  • International Neuroethics Society
  • Society for Behavioral Neuroendocrinology
  • Society For Neuroscience
  • American Psychological Association
  • International Parkinson and Movement Disorder Society
  • American Neurological Association
  • National Institute Of Environmental Health Sciences
  • The American Society of Neuroimaging
  • American Board Of Psychiatry And Neurology, Inc.
  • American Clinical Neurophysiology Society
  • International Neuropsychological Society
  • Southern Clinical Neurological Society
  • International Parkinson And Movement Disorder Society

Products for Neurological Treatments

This above statistic displays the global revenue of Abilify from Bristol-Myers Squibb from 2011 to 2014. In the United States alone, Abilify generated a revenue of 2.1 million U.S. dollars in 2012. Abilify is an antipsychotic agent that is used to treat various conditions such as schizophrenia, bipolar mania disorder, and major depressive disorder.

Gross Profit Margin of Neuropharmaceutical related companies

Market Capitalization of Neuropharmaceutical companies: In 2014, investors provided $3.3 billion into firms that are developing drugs for brain-destroying or psychiatric illnesses. Some big drug companies, including Johnson & Johnson, Roche and Novartis, are finding ways to reinvigorate their efforts. New medicines for severe depression, psychosis and schizophrenia could reach the market within the next few years, and treatments for Alzheimer’s, Parkinson’s and some forms of autism are a real possibility, too.

Sales Profile of Neuropharmaceutical companies

Research Fund: NIH (National Institute of Health) and NSFC (Nature Science Foundation of China) provided fund for the neurological disorders such as dementia, schizophrenia, stroke, parkinson’s, epilepsy.

Institutes funding for research

  1. The US National Institutes of Health fund a Neuropharmacology Laboratory project, Universitat Pompeu Fabra, Barcelona
  2. Neuropharmacology Program, The National Institute of Mental Health (NIMH)
  3. McKnight Endowment Fund for Neuroscience
  • The statistic depicts the research and development expenditure of the entire pharmaceutical industry of the United States from 1995 to 2014. In 2004, the expenditure of the entire U.S. pharmaceutical industry on research and development came to 47.6 billion U.S. dollars.